Washington, D.C. 20549





Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 25, 2018


Tandem Diabetes Care, Inc.

(Exact name of registrant as specified in its charter)








(State or other jurisdiction

of incorporation)



File Number)


(I.R.S. Employer
Identification No.)



 11075 Roselle Street, San Diego, CA





 (Address of principal executive offices)


(Zip Code)


Registrant’s telephone number, including area code: (858) 366-6900


(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company 


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 



Item 7.01Regulation FD Disclosure


On September 25, 2018, Tandem Diabetes Care, Inc. (the “Company”) issued a press release announcing that the Company increased its 2018 sales guidance and provided estimated sales results for the quarter ending September 30, 2018. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.


The information provided under this Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.


Item 9.01Financial Statements and Exhibits


(d) Exhibits.





Press release of Tandem Diabetes Care, Inc. dated September 25, 2018.





Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Tandem Diabetes Care, Inc.





/s/ David B. Berger



David B. Berger



Executive Vice President, General Counsel and Secretary

Date:  September 25, 2018






Exhibit 99.1






Tandem Diabetes Care Increases 2018 Sales Guidance and Provides Estimated Third Quarter Sales Results

Continued Domestic Demand and International Launch of the t:slim X2 Insulin Pump Drive Growth


San Diego, September 25, 2018  Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps with continuous glucose monitoring integration, today announced that it has increased its 2018 sales guidance to $150 million to $158 million, from $140 million to $148 million, following continued strong domestic sales in the third quarter and the recent launch of the t:slim X2™ Insulin Pump in select international markets. Compared to 2017 sales of approximately $108 million, the revised guidance range represents annual sales growth of 39 percent to 47 percent.


The revised sales guidance includes a projected $7 million to $8 million of sales in select geographies outside of the United States, which commenced in August 2018. Sales, training and customer service outside of the United States are being provided by regional distribution partners, except in Canada. The t:slim X2 Insulin Pump is currently under review by Health Canada. The Company is planning to launch in Canada in the fourth quarter, subject to obtaining regulatory approval.


Sales for the third quarter of 2018 are estimated to be in the range of $42 million to $44 million, which represents quarterly sales growth of 56 percent to 63 percent compared to approximately $27 million in the third quarter of 2017. Sales estimates for the third quarter of 2018 include approximately $2 million of projected sales in select geographies outside the United States.


“The sales momentum we are experiencing both domestically and internationally reinforces that we are successfully addressing the needs of people with diabetes worldwide,” said Kim Blickenstaff, President and Chief Executive Officer. “We are increasing our sales guidance as a reflection of this and the tremendous feedback we’ve been receiving on the t:slim X2 Insulin Pump.”


About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. ( is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. Tandem takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem manufactures and sells the t:slim X2™ Insulin Pump, which features integrated continuous glucose monitoring. Tandem is based in San Diego, California.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2 and $TNDM.

Follow Tandem Diabetes Care on Facebook at

Follow Tandem Diabetes Care on LinkedIn at


Tandem Diabetes Care is a registered trademark and t:slim X2 is a trademark of Tandem Diabetes Care, Inc.





Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements relate to, among other things, the Company’s estimated sales for the quarter ended September 30, 2018, the Company’s projected sales for 2018, the timing of review of its Canadian health care medical device license application, and the anticipated commercial launch of a Tandem product in Canada in the fourth quarter of 2018. The forward-looking statements made in this press release are subject to numerous risks and uncertainties and actual results could be materially different from the results projected or implied by these statements. For example, the Company’s actual estimated sales for the quarter ended September 30, 2018 have been projected based on information available to management prior to the end of the reporting period and have not been subject to any review procedures by our independent registered public accounting firm. In addition, the Company’s ability to achieve its projected sales results for 2018 will be impacted by the continued market acceptance of the Company’s new products by healthcare providers, third-party payors and people with diabetes; the timing and pattern of future orders from the Company’s independent distributors; uncertainty associated with the timing and outcome of Health Canada’s review of the t:slim X2 Insulin Pump currently pending regulatory approval; the Company’s ability to manufacture products in commercial quantities at an acceptable cost and in accordance with quality requirements; and the potential that newer products that compete with the Company’s products, or other technological breakthroughs for the monitoring, treatment or prevention of diabetes, may render our products obsolete or less desirable. Other risks and uncertainties are identified in our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and other documents that we file with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events or other factors.


Tandem Diabetes Care Contact Information:

Media: Steve Sabicer, 714-907-6264,

Investors: Susan Morrison, 858-366-6900 x7005,



# # #